SecBot SecBot

TCRX

TScan Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001783328 Biotech & Drug Discovery
$0.1450 −0.02 (−9.94%)
Nov 16 4:00 PM ET · prev $0.1610
Market cap
$10.7M
Nano cap
Consensus
Buy
64% Buy or better · 11 analysts
Median target
$1.00
+590% · range $1.00–1.00
1 year
−85.1%
from $0.9700 · Nov 17
30 days
−31.0%
from $0.2100
52-week range
$0.1450–1.43
at the low
Avg volume 20D
462.5K
shares / day
Short interest
2.02M
≈3.2% of shares · −11.3%
Days to cover
4.7
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 3 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 7/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q3 2026: 2 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    7 of 11 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −11.3% to 2.02M shares. 4.7 days to cover, ≈3.2% of shares.

  • TrendDOWNTREND

    43% below its 50-day average. New closing low $0.1450 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.TRIM597,865$188.0K
MARSHALL WACE, LLPTRIM269,613$83.6K
UBS Group AGADD108,247$34.1K
MORGAN STANLEYTRIM104,749$32.9K
JANE STREET GROUP, LLCTRIM90,185$28.4K
HRT FINANCIAL LPTRIM62,643$19.0K
FMR LLCADD2,000$629.00
JPMORGAN CHASE & CONEAR_EXIT1,715$545.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 64% rate it Buy or better
Strong Buy2Buy5Hold4Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +590%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 8, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Sep 3, 2026Wedbush
DOWNGRADE
DOWNGRADENeutral
Sep 2, 2026Needham
DOWNGRADE
DOWNGRADEHold
Aug 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 23, 2026Wedbush
REITERATE
REITERATEOutperform
Jun 23, 2026Needham
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 1, 2026
MacBeath Gavin
Chief Executive Officer
Oct 1, 2026
AWARD1,000,000 sh
Oct 1, 2026
ZDRAVESKI ZORAN
See Remarks
Oct 1, 2026
AWARD300,000 sh
May 20, 2026
Gruia Gabriela
Director
May 20, 2026
AWARD67,000 sh
May 20, 2026
Dorton Katina
Director
May 20, 2026
AWARD67,000 sh
May 20, 2026
Klencke Barbara
Director
May 20, 2026
AWARD67,000 sh
May 20, 2026
Woods Keith
Director
May 20, 2026
AWARD67,000 sh
May 20, 2026
Nicholson Garry A
Director
May 20, 2026
AWARD67,000 sh
May 20, 2026
BAKER BROS. ADVISORS LP
Director
May 20, 2026
AWARD67,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY-$0.83-$0.88–-$0.78-6.8%$2.6M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
2,020,541
shares short
-11.3%
vs prior settlement
4.7
days to cover
≈3.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
The company paused enrollment in its Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital and announced a…
8-K · Impact 7/10
Nov 12, 2026 Earnings
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Oct 26, 2026 SEC
TScan Therapeutics is holding a special meeting on November 20, 2026, to seek stockholder approval for a reverse stock…
DEF 14A · Impact 6/10
Oct 16, 2026 SEC
Two board members, Garry Nicholson and Gabriela Gruia, M.D., resigned from TScan Therapeutics' board effective October…
8-K · Impact 2/10
Oct 1, 2026 Insider
MacBeath Gavin was granted 1,000,000 shares
Chief Executive Officer
Oct 1, 2026 Insider
ZDRAVESKI ZORAN was granted 300,000 shares
See Remarks
Sep 30, 2026 Inst.
BlackRock, Inc. · TRIM
597,865 shares ($188.0K)
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · TRIM
269,613 shares ($83.6K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

13 filings · 2 press releases · 1 bullish · 6 bearish · 6 neutral
All TCRX filing & press-release reports (15)